Journal Mobile Options
Table of Contents
Vol. 12, No. 2, 2005
Issue release date: March 2005
Neuroimmunomodulation 2005;12:67–80

Complement Component C5a Is Integral to the Febrile Response of Mice to Lipopolysaccharide

Li S. · Boackle S.A. · Holers V.M. · Lambris J.D. · Blatteis C.M.
Departments of aPhysiology, University of Tennessee Health Science Center, Memphis, Tenn., bMedicine, University of Colorado Health Science Center, Denver, Colo., and cPathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pa., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Objectives: The complement system is critical to the febrile response of mice to intraperitoneally administered lipopolysaccharide (LPS). We previously identified C3 and C5 as two components potentially involved in this response. This study was designed to examine whether the complement system is also pivotal in the response of mice to intravenously or intracerebroventricularly injected LPS, to distinguish between C3 and C5 and their cognate derivatives as the essential mediator(s), and to determine whether the failure of complement-deficient mice to develop a fever could be due to their possible inability to secrete pyrogenic cytokines. Methods: Wild-type (WT; C57BL/6J) mice, hypocomplemented or not by intravenously injected cobra venom factor (10 U/mouse), and C3-, CR3- and C5-sufficient and -deficient mice were intravenously challenged with LPS (0.25 µg/mouse); WT and C3–/– mice pretreated with a C5a receptor antagonist (C5aRa) were similarly challenged. In addition, the serum levels of interleukin (IL)-1β, tumor necrosis factor (TNF)-α and IL-6 were compared in LPS-treated C5+/+ and C5–/– mice. Results: LPS induced a 1°C rise in core temperature in all the mice, except C5–/– mice and those pretreated with C5aRa. C5+/+ and C5–/– mice challenged intracerebroventricularly with LPS exhibited identical febrile responses. LPS induced similar increases in the serum levels of IL-1β, TNFα and IL-6 in C5+/+ and C5–/– mice. Conclusions: C5a is crucial for the development of febrile responses to LPS in mice; its site of action is peripheral, not central. The possibility that an inability to produce cytokines could account for the failure of C5–/– mice to develop a fever is not supported.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Blatteis CM, Sehic E, Li S: Pyrogen sensing and signaling: Old views and new concepts. Clin Infect Dis 2000;31:S168–S177.

    External Resources

  2. Vukajlovich SW: Interactions of LPS with serum complement; in Ryan JL, Morrison DC (eds): Bacterial Endotoxic Lipopolysaccharides. Boca Raton, CRC Press, 1992, vol 2, pp 213–235.
  3. Daniele R, Singh H, Appert HE, Pairent FW, Howard JM: Lymphatic absorption of intraperitoneal endotoxin in the dog. Surgery 1970;67:484–487.
  4. Olofsson P, Nylander G, Olsson P: Endotoxin: Routes of transport in experimental peritonitis. Am J Surg 1986;151:443–447.
  5. Romanovsky AA, Ivanov AI, Lenczowski MJP, Kulchitsky VA, Van Dam A, Poole S, Homer LD, Tilders FJH: Lipopolysaccharide transport from the peritoneal cavity to the blood: Is it controlled by the vagus nerve? Auton Neurosci 2000;85:133–140.
  6. Mathison JC, Ulevitch RJ: The clearance, tissue distribution, and cellular localization of intravenously injected lipopolysaccharide in rabbits. J Immunol 1979;123:2133–2143.
  7. Mori K, Matsumoto K, Gans H: On the in vivo clearance and detoxification of endotoxin by lung and liver. Ann Surg 1973;177:159–163.
  8. Hinglais N, Kazatchkine MD, Mandet C, Appay MD, Bariety J: Human liver Kupffer cells express CR1, CR3, and CR4 complement receptor antigen. An immunohistochemical study. Lab Invest 1989;61:509–514.
  9. Schalf G, Schieferdecker HL, Rothermel E, Jungermann K, Gotze O: Differential expression of the C5a receptor on the main cell types of rat liver as demonstrated with a novel monoclonal antibody and by C5a anaphylatoxin-induced Ca2+ release. Lab Invest 1999;79:1287–1297.
  10. Schieferdecker HL, Rothermel E, Timmermann A, Gotze O, Jungermann K: Anaphylatoxin C5a receptor mRNA is strongly expressed in Kupffer and stellate cells and weakly in sinusoidal endothelial cells but not in hepatocytes of normal rat liver. FEBS Lett 1997;406:305–308.
  11. Cavaillon JM, Fitting C, Haeffner-Cavaillon N: Recombinant C5a enhances interleukin-1 and tumor necrosis factor release by lipopolysaccharide-stimulated monocytes and macrophages. Eur J Immunol 1990;20:253–257.
  12. Sehic E, Li S, Ungar AL, Blatteis CM: Complement reduction impairs the febrile response of guinea pigs to endotoxin. Am J Physiol 1998;274:R1594–R1603.
  13. Li S, Sehic E, Wang Y, Ungar AL, Blatteis CM: Relation between complement and the febrile response of guinea pigs to systemic endotoxin. Am J Physiol 1999;277:R1635–R1645.
  14. Li S, Holers VM, Boackle SA, Blatteis CM: Modulation of mouse endotoxic fever by complement. Infect Immun 2002;70:2519–2525.
  15. Gasque P, Dean YD, McGreal EP, Van Beek J, Morgan BP: Complement components of the innate immune system in health and disease in the CNS. Immunopharmacology 2000;49:171–186.
  16. Morgan BP, Gasque P: Expression of complement in the brain: Role in health and disease. Immunol Today 1996;17:461–466.
  17. Nadeau S, Rivest S: The complement system is an integrated part of the natural innate immune response in the brain. FASEB J 2001;15:1410–1412.
  18. Blatteis CM, Sehic E: Fever: How may circulating pyrogens signal the brain? News Physiol Sci 1997;12:1–9.
  19. Boulant JA: Hypothalamic neurons regulating body temperature; in Fregly MJ, Clark CM (eds): Handbook of Physiology. Section 4: Environmental Physiology, vol 1. New York, Oxford University Press, 1996.
  20. Blatteis CM, Sehic E: Prostaglandin E2: A putative fever mediator; in Mackowiak PA (ed): Fever: Basic Mechanisms and Management, ed 2. New York, Raven-Lippincott, 1997, pp 117–148.
  21. Sekine H, Reilly CM, Molano ID, Garnier G, Circolo A, Ruiz P, Holers VM, Boackle SA, Gilkeson GS: Complement component C3 is not required for full expression of immune complex glomerulonephritis in MRL/lpr mice. J Immunol 2001;166:6444–6451.
  22. Circolo A, Garnier G, Fukuda W, Wang X, Hidvegi T, Szalai AJ, Briles DE, Volanakis JE, Wetsel RA, Colten HR: Genetic disruption of the murine complement C3 promoter region generates deficient mice with extrahepatic expression of C3 mRNA. Immunopharmacology 1999;42:135–149.
  23. Institute of Laboratory Animal Resources Commission on Life Science: Guide for the Care and Use of Laboratory Animals. Washington, National Academy Press, 1996, pp 21–36.
  24. World Medical Association: Guiding principles for research involving animal and human beings. Am J Physiol Regul Integr Comp Physiol 2002;283:R281–R283.
  25. Riedemann NC, Guo R, Neff TA, Laudes IJ, Kellers KA, Sarma VJ, Markiewski MM, Mastellos D, Strey CW, Pierson CL, Lambris JD, Zetoune FS, Ward PA: Increased C5a receptor expression in sepsis. J Clin Invest 2002;110:101–108.
  26. Haley TJ, McCormick WG: Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse. Br J Pharmacol 1957;12:12–15.
  27. Kondo A, Togari A: In vivo stimulation of sympathetic nervous system modulates osteoblastic activity in mouse calvaria. Am J Physiol Endocrinol Metab 2003;285:E661–E667.
  28. Franklin KBJ, Paxinos G: The Mouse Brain in Stereotaxic Coordinate. San Diego, Academic Press, 1997.
  29. Gordon CJ: Temperature Regulation in Laboratory Rodents. Cambridge, Cambridge University Press, 1993.
  30. Li S, Goorha S, Ballou LR, Blatteis CM: Intracerebroventricular interleukin-6, inflammatory protein-1β and IL-18: Pyrogenic and PGE2-mediated? Brain Res 2003;992:76–84.
  31. Oka T, Oka K, Kobayashi T, Sugimoto Y, Ichikawa A, Ushikubi F, Narumiya S, Saper CB: Characteristics of thermoregulatory and febrile responses in mice deficient in prostaglandin EP1 and EP3 receptors. J Physiol 2003;551:945–954.
  32. Leon LR, Kozak W, Rudolph K, Kluger MJ: An antipyretic role for interleukin-10 in LPS fever in mice. Am J Physiol 1999;45:R81–R89.
  33. Kohl J: Anaphylatoxins and infectious and non-infectious inflammatory diseases. Mol Immunol 2001;38:175–187.
  34. Gross V, Andus T: Human recombinant C5a enhances lipopolysaccharide-induced synthesis of interleukin-6 by human monocytes. Eur J Clin Invest 1992;22:271–276.
  35. Hespeling U, Puschel GP, Jungermann K, Gotze O, Zwirner J: Stimulation of glycogen phosphorylase in rat hepatocytes via prostanoid release from Kupffer cells by recombinant rat anaphylatoxin C5a but not by native human C5a in hepatocyte/Kupffer cell co-cultures. FEBS Lett 1995;372:108–112.
  36. Okusawa S, Dinarello CA, Yancey KB, Endres S, Lawley TJ, Frank MM, Burke JF, Gelfand JA: C5a induction of human interleukin 1:Synergistic effect with endotoxin or interferon-γ. J Immunol 1987;139:2635–2640.
  37. Okusawa S, Yancey KB, Van der Meer JWM, Endres S, Lonnemann G, Hefter K, Frank MM, Burke JF, Dinarello CA, Gelfand JA: C5a stimulates secretion of tumor necrosis factor from human mononuclear cells in vitro: Comparison with secretion of interleukin 1β and interleukin 1α. J Exp Med 1988;168:443–448.
  38. Pestel S, Jungermann K, Gotze O, Schieferdecker HL: Inhibition by prostaglandin E2 of anaphylatoxin C5a- but not zymosan-induced prostanoid release from rat Kupffer cells. Lab Invest 2002;82:463–471.
  39. Schieferdecker HL, Pestel S, Rothermel E, Puschel GP, Gotze O, Jungermann K: Stimulation by anaphylatoxin C5a of glycogen phosphorylase in rat hepatocytes via prostanoid release from hepatic stellate cells but not sinusoidal endothelial cells. FEBS Lett 1998;434:245–250.
  40. Schieferdecker HL, Schlaf G, Jungermann K, Gotze O: Functions of anaphylatoxin C5a in rat liver: Direct and indirect actions on nonparenchymal and parenchymal cells. Int Immunopharmacol 2001;1:469–481.
  41. Schindler R, Gelfand JA, Dinarello CA: Recombinant C5a stimulates transcription rather than translation of interleukin-1 (IL-1) and tumor necrosis factor: Translation signal provided by lipopolysaccharide or IL-1 itself. Blood 1990;76:1631–1638.
  42. Scholz W, McClurg MR, Cardenas GJ, Smith M, Noonan DJ, Hugli TE, Morgan EL: C5a-mediated release of interleukin-6 by human monocytes. Clin Immunol Immunopathol 1990;57:297–307.
  43. Haviland DL, McCoy RL, Whitehead WT, Akama H, Molmenti EP, Brown A, Haviland JC, Parks WC, Perlmutter DH, Wetsel RA: Cellular expression of the C5a anaphylatoxin receptor (C5aR): Demonstration of C5aR on nonmyeloid cells of the liver and lung. J Immunol 1995;154:1861–1869.
  44. McCoy R, Haviland DL, Molmenti EP, Ziambaras T, Wetsel RA, Perlmutter DH: N-formylpeptide and complement C5a receptors are expressed in liver cells and mediate hepatic acute phase gene regulation. J Exp Med 1995;182:207–217.
  45. Wetsel RA: Expression of the complement C5a anaphylatoxin receptor (C5aR) on non-myeloid cells. Immunol Lett 1995;44:183–187.
  46. Zwirner J, Fayyazi A, Gotze O: Expression of the anaphylatoxin C5a receptor in non-myeloid cells. Mol Immunol 1999;36:877–884.
  47. Schalf G, Schmitz M, Rothermel E, Jungermann K, Schieferdecker HL, Gotze O: Expression and induction of anaphylatoxin C5a receptors in the rat liver. Histol Histopathol 2003;18:299–308.

    External Resources

  48. Akatsu H, Abe M, Miwa T, Tateyama H, Maeda S, Okada N, Kojima K, Okada H: Distribution of rat C5a anaphylatoxin receptor. Microbiol Immunol 2002;46:863–874.
  49. Fukuoka Y, Ember JA, Hugli TE: Cloning and characterization of rat C3a receptor: Differential expression of rat C3a and C5a receptors by LPS stimulation. Biochem Biophys Res Commun 1998;242:663–668.
  50. Haynes DR, Harkin DG, Bignold LR, Hutchens MJ, Taylor SM, Fairlie DP: Inhibition of C5a-induced neutrophil chemotaxis and macrophage cytokine production in vitro by a new C5a receptor antagonist. Biochem Pharmacol 2000;60:729–733.
  51. Huber-Lang M, Sarma VJ, Lu KT, McGuire SR, Padgaonkar VA, Guo R, Younkin EM, Kunkel RG, Ding J, Erickson R, Curnutte JT, Ward PA: Role of C5a in multiorgan failure during sepsis. J Immunol 2001;166:1193–1199.
  52. Smedegard G, Cui L, Hugli TE: Endotoxin-induced shock in the rat: A role for C5a. Am J Pathol 1989;135:489–497.
  53. Czermak BJ, Friedl HP, Ward P: Complement, cytokine, and adhesion molecule expression in inflammatory reactions. Proc Assoc Am Physicians 1998;110:306–312.
  54. Hansch GM, Seitz M, Betz M: Effect of the late complement components C5b-9 on human monocytes: Release of prostanoids, oxygen radicals, and of a factor inducing cell proliferation. Int Arch Allergy Appl Immunol 1987;82:317–320.
  55. Medvedev AE, Flo T, Ingalls RR, Golenbock DT, Teti G, Vogel SN, Espevik T: Involvement of CD14 and complement receptors CR3 and CR4 in nuclear factor-kappaB activation and TNF production induced by lipopolysaccharide and group B streptococcal cell walls. J Immunol 1998;160:4535–4542.
  56. Wright SD, Ramos RA, Hermanowski-Vosatka A, Rockwell P, Detmers PA: Activation of the adhesive capacity of CR3 on neutrophils by endotoxin: Dependence on lipopolysaccharide binding protein and CD14. J Exp Med 1991;173:1281–1286.
  57. Haziot A, Tsuberi BZ, Goyert SM: Neutrophil CD14: Biochemical properties and role in the secretion of tumor necrosis factor-alpha in response to lipopolysaccharide. J Immunol 1993;150:5556–5565.
  58. Ingalls RR, Golenbock DT: CD11c/CD18, a transmembrane signaling receptor for lipopolysaccharide. J Exp Med 1995;181:1473–1479.
  59. Perera PY, Mayadas TN, Takeuchi O, Akira S, Zaks-Zilberman M, Goyert SM, Vogel SN: CD11b/CD18 acts in concert with CD14 and Toll-like receptor (TLR) 4 to elicit full lipopolysaccharide and taxol-inducible gene expression. J Immunol 2001;166:574–581.
  60. Zarewych DM, Kindzelskii AL, Todd RF 3rd, Petty HR: LPS induces CD14 association with complement receptor type 3, which is reversed by neutrophil adhesion. J Immunol 1996;156:430–433.
  61. Wright SD, Detmers PA, Aida Y, Adamowski R, Anderson DC, Chad Z, Kabbash LG, Pabst MJ: CD18-deficient cells respond to lipopolysaccharide in vitro. J Immunol 1990;144:2566–2571.
  62. Rosenkranz AR, Coxon A, Maurer M, Gurish MF, Austen KF, Friend DS, Galli SJ, Mayadas TN: Impaired mast cell development and innate immunity in Mac-1 (CD11b/CD18, CR3)-deficient mice. J Immunol 1998;161:6463–6467.
  63. Asarian L, Silverman AJ, Silver R: Mast cell deficient mice lack elements of the acute-phase response following bacterial infection (program No. 773.9. 2002). Abstract Viewer/Itinerary Planner. Washington, Society for Neuroscience, 2002. CD-ROM.
  64. Cochrane CG, Müller-Eberhard HJ, Aikin BS: Depletion of plasma complement in vivo by a protein from cobra venom: Its effects on various immunological reactions. J Immunol 1970;105:55–69.
  65. Van den Berg CW, Aerts PC, Van Dijk H: In vivo anti-complementary activities of the cobra venom factors from Naja naja and Naja haje. J Immunol Methods 1991;136:287–294.
  66. Vogel CW, Bredehorst R, Fritzinger DC, Grunwald T, Ziegelmuller P, Koek MA: Structure and function of cobra venom factor, the complement-activating protein in cobra venom. Adv Exp Med 1996;391:97–114.
  67. Winkelstein JA, Johnson JP, Swift AJ, Ferry F, Yolken R, Cork LC: Genetically determined deficiency of the third component of complement in the dogs: In vitro studies on the complement system and complement-mediated serum activities. J Immunol 1982;129:2598–2602.
  68. Kitamura K, Matsumoto M, Nagaki K: C3-independent immune hemolysis of EAC14oxy2 cells by C5-C9 without participation of C3. Immunology 1984;53:575–582.
  69. Kitamura K, Nishimukai H, Sano Y, Nagaki K: Study of C3-like factor in the serum of a C3-deficient subject. Immunology 1984;51:239–245.
  70. Kitamura K, Tsuboi M, Nagaki K: The activation of C5 in the fluid phase and in the absence of C3 through the classical pathway of the complement system. Immunology 1986;58:459–465.
  71. Masaki T, Matsumoto M, Yasuda R, Levine RP, Kitamura H, Seya T: A covalent dimer of complement C4b serves as a subunit of a novel C5 convertase that involves no C3 derivatives. J Immunol 1991;147:927–932.
  72. Feleder C, Li Z, Perlik V, Evans A, Blatteis CM: The spleen modulates the febrile response of guinea pigs to LPS. Am J Physiol Regul Integr Comp Physiol 2003;284:R1466–R1476.
  73. Li Z, Blatteis CM: Fever onset is linked to the appearance of lipopolysaccharide in the liver. J Endotoxin Res, in press.
  74. Colten HR, Ooi YM, Edelson PJ: Synthesis and secretion of complement proteins by macrophages. Ann N Y Acad Sci 1979;332:482–490.
  75. Hetland G, Johnson E, Aasebo U: Human alveolar macrophages synthesize the functional alternative pathway of complement and active C5 and C9 in vitro. Scand J Immunol 1986;24:603–608.
  76. Hetland G, Johnson E, Royset P, Eskeland T: Human alveolar macrophages and monocytes generate the functional classical pathway of complement in vitro. Acta Pathol Microbiol Immunol Scand 1987;95:117–122.
  77. Ooi YM, Harris DE, Edelson PJ, Colten HR: Post-translational control of complement (C5) production by resident and stimulated mouse macrophages. J Immunol 1980;124:2077–2081.
  78. Whaley K: Biosynthesis of the complement components and the regulatory proteins of the alternative complement pathways by human peripheral blood monocytes. J Exp Med 1980;151:501–516.
  79. Huber-Lang M, Younkin EM, Sarma JV, Riedemann N, McGuire SR, Lu KT, Kunkel R, Younger JG, Zetoune FS, Ward PA: Generation of C5a by phagocytic cells. Am J Pathol 2002;161:1849–1859.
  80. Snyderman R, Shin HS, Dannenberg AM: Macrophage proteinase and inflammation: Production of chemotactic activity from the fifth complement by macrophage proteinase. J Immunol 1972;109:896–898.
  81. Wiggins RC, Giclas PC, Henson PM: Chemotactic activity generated from the fifth component of complement by plasma kallikrein of the rabbit. J Exp Med 1981;153:1391–1404.
  82. Wingrove JA, Di Scipio RG, Chen Z, Potempa J, Travis J, Hugli TE: Activation of complement components C3 and C5 by a cysteine proteinase (gingipain-1) from Porphyromonas (bacteroides) gingivalis. J Biol Chem 1992;267:18902–18907.
  83. Gasque P, Chan P, Fontaine M, Ischenko A, Lamacz M, Gotze O, Morgan BP: Identification and characterization of the complement C5a anaphylatoxin receptor on human astrocytes. J Immunol 1995;155:4882–4889.
  84. Gasque P, Singhrao SK, Neal JW, Gotze O, Morgan BP: Expression of the receptor for complement C5a (CD88) is up-regulated on reactive astrocytes, microglia, and endothelial cells in the inflamed human central nervous system. Am J Pathol 1997;150:31–41.
  85. Haga S, Aizawa T, Ishii T, Ikeda K: Complement gene expression in mouse microglia and astrocytes in culture: Comparisons with mouse peritoneal macrophages. Neurosci Lett 1996;216:191–194.
  86. O’Barr SA, Caguioa J, Gruol D, Perkins G, Ember JA, Hugli T, Cooper NR: Neuronal expression of a functional receptor for the C5a complement activation fragment. J Immunol 2001;166:4154–4162.
  87. Osaka H, McGinty A, Hoepken UE, Lu B, Gerard C, Pasinetti GM: Expression of C5a in mouse brain: Role in signal transduction and neurodegeneration. Neuroscience 1999;88:1073–1082.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50